Artelo Biosciences Inc ARTL 深 沪
交易中 05-11 10:32:17 美东时间
2.62
+0.080
+3.15%
华盛通- 最 高3.04
- 今 开2.51
- 成交量 3.05万股
- 最 低 2.51
- 昨 收 2.54
- 总市值 11.16万
- 52周最高 28.60
- 市盈率 静 --
- 换手率 71.51%
- 52周最低 0.9017
- 委 比 97.15%
- 总股本 4.26万
- 历史最高 28.60
- 量 比 2.40
- 振 幅 20.87%
- 历史最低 0.26
- 每 手 1
- 风险率 4.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Crude Oil Surges 4%; US Consumer Sentiment Declines In March
U.S. stocks down, NASDAQ drops 1.5% on Friday. Energy shares up, consumer discretionary down. University of Michigan's Consumer Sentiment Index falls.
03-28 00:40
Artelo Biosciences Stock Soars After Withdrawing SEC Filing
Artelo Biosciences Inc. shares are trading higher Friday after withdrawing its SEC Registration Statement, citing no plan to sell securities.
03-27 21:36
Artelo Biosciences Expands Into $16.3B Glaucoma Market Via Investigator‑Sponsored Study, Underscoring Multi‑Platform Pipeline Durability Across High‑Value Therapeutic Areas
Artelo Biosciences, Inc. (NASDAQ:ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinical study—an announcement that
03-25 19:34
Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Shares of Keysight Technologies Inc (NYSE:KEYS) rose sharply in pre-market trad...
02-24 18:21
Artelo Biosciences Has Been Granted European Patent Number EP4259111 Titled "PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABINOID AGONIST"
https://register.epo.org/application?number=EP21827629
2025-12-02 04:58
Maxim Group Downgrades Artelo Biosciences to Hold
Maxim Group analyst Jason McCarthy downgrades Artelo Biosciences (NASDAQ:ARTL) from Buy to Hold.
2025-11-19 23:48
Artelo Biosciences Announces Reverse Stock Split
Artelo Biosciences approves a 6-for-1 reverse stock split effective June 13, 2025, to increase share price and meet NASDAQ listing requirements.
2025-06-11 12:30
New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression
Artelo Biosciences published a study highlighting the therapeutic potential of FABP inhibitors, particularly ART26.12, in treating anxiety, depression, and pain by targeting lipid signaling pathways. Clinical trials for ART26.12 are progressing with expected results this quarter.
2025-06-02 13:00
